Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Biocartis Group NV    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Biocartis : Results of the Extraordinary Shareholders' Meeting held on 25 September 2020

09/25/2020 | 11:50am EST

PRESS RELEASE

REGULATED INFORMATION

25 September 2020, 17:40 CEST

Results of the Extraordinary Shareholders' Meeting

held on 25 September 2020

Mechelen, Belgium, 25 September 2020 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), held its extraordinary shareholders' meeting today.

The shareholders approved all items on the agenda of the extraordinary shareholders' meeting. All documents relating to the shareholders' meeting can be consulted on the websiteof the Company.

--- END ---

More information:

Renate Degrave

Head of Corporate Communications & Investor Relations Biocartis

e-mail

rdegrave@biocartis.com

tel

+32

15 631 729

mobile

+32

471 53 60 64

@Biocartis_ www.linkedin.com/Biocartis

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result,real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com.Follow us on Twitter: @Biocartis_.

Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward- looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

1

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Biocartis Group NV published this content on 25 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 September 2020 15:49:02 UTC


© Publicnow 2020
All news about BIOCARTIS GROUP NV
11/17BIOCARTIS : Announces Publication of Large Multi-Center Comparison Study with Id..
PU
11/17PRESS NEWS BIOCARTIS GROUP NV : Biocartis Announces Publication of Large Multi-C..
AQ
11/16BIOCARTIS : Announces Ten Idylla™ Studies to be Published at Virtual AMP (..
PU
11/16PRESS NEWS BIOCARTIS GROUP NV : Biocartis Announces Ten Idylla™ Studies t..
AQ
11/12BIOCARTIS : Q3 2020 business update
PU
11/12PRESS NEWS BIOCARTIS GROUP NV : Biocartis q3 2020 business update
AQ
11/12BIOCARTIS GROUP NV : 3rd quarter earnings
CO
11/10PRESS NEWS BIOCARTIS GROUP NV : Biocartis Announces CE-marking of its Fully Auto..
AQ
11/03BIOCARTIS : Announces Partnership with Endpoint Health to Develop Novel Companio..
PU
11/03BIOCARTIS : and GeneproDx To Collaborate on Fully Automated ThyroidPrint® test o..
PU
More news
Financials
Sales 2020 44,7 M 52,9 M 52,9 M
Net income 2020 -57,7 M -68,3 M -68,3 M
Net Debt 2020 113 M 134 M 134 M
P/E ratio 2020 -4,35x
Yield 2020 -
Capitalization 267 M 316 M 316 M
EV / Sales 2020 8,51x
EV / Sales 2021 7,25x
Nbr of Employees 499
Free-Float 81,4%
Chart BIOCARTIS GROUP NV
Duration : Period :
Biocartis Group NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCARTIS GROUP NV
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 7,75 €
Last Close Price 4,74 €
Spread / Highest target 89,9%
Spread / Average Target 63,5%
Spread / Lowest Target 42,4%
EPS Revisions
Managers
NameTitle
Herman Verrelst Chief Executive Officer & Executive Director
Christian Reinaudo Independent Chairman
Piet Houwen Chief Operating Officer
Jean-Marc Roelandt Chief Financial Officer
Benoit Devogelaere Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
BIOCARTIS GROUP NV-17.13%317
MASIMO CORPORATION56.88%13 651
NOVOCURE LIMITED57.07%13 474
ASAHI INTECC CO., LTD.2.34%8 221
GETINGE AB6.55%5 863
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.42.18%4 360